Filing Flows › Aquestive Therapeutics (AQST) › Q2 2026 › vs Q2 2025
Aquestive Therapeutics (AQST) Q2 2026 vs Q2 2025 (year over year)
Aquestive Therapeutics's revenue rose $3.8M (+38%) from $10.0M in Q2 2025 to $13.8M in Q2 2026. The biggest changes: Manufacture and supply revenue +$2.3M (+24%); License and royalty revenue (a) +$487K (+58%); Co-development and research fees +$204K (+54%).
Aquestive Therapeutics, Q2 2026: revenue $13.8M (+38% year over year), operating margin -59.5%, net loss $22.9M, operating cash flow −$9.4M. The chart draws each line against Q2 2025, the increases inside each band.
Every line
| Line | Q2 2026 | Q2 2025 | Change | % |
|---|---|---|---|---|
| Manufacture and supply revenue | $11.9M | $9.6M | $2.3M | +24% |
| License and royalty revenue (a) | $1.3M | $839K | $487K | +58% |
| Co-development and research fees | $582K | $378K | $204K | +54% |
| Revenue | $13.8M | $10.0M | $3.8M | +38% |
| Net loss | $22.9M | $13.5M | $9.3M | +69% |
| Costs & expenses | $36.7M | $23.6M | $13.1M | +56% |
| Operating costs | $22.0M | $21.4M | $671K | +3% |
| Interest & other, net | $14.6M | $2.2M | $12.5M | +572% |
| Cost of revenue | $4.0M | $4.6M | −$544K | -12% |
| Research & development | $4.0M | $4.1M | −$143K | -3% |
| SG&A | $14.1M | $12.7M | $1.4M | +11% |
| Operating cash sources | $22.9M | $13.5M | $9.3M | +69% |
| Depreciation | $136K | $140K | −$4K | -3% |
| Share-based compensation | $2.9M | $1.9M | $1.0M | +54% |
| Working capital & other | $10.4M | $3.6M | $6.8M | +188% |
| Cash used in operations | $9.4M | $7.9M | $1.5M | +19% |
| Net loss absorbed | $22.9M | $13.5M | $9.3M | +69% |
Questions
How much did Aquestive Therapeutics's revenue grow year over year in Q2 2026?
Aquestive Therapeutics's revenue rose $3.8M (+38%) from $10.0M in Q2 2025 to $13.8M in Q2 2026.
What drove Aquestive Therapeutics's revenue change in Q2 2026?
Manufacture and supply revenue +$2.3M (+24%); License and royalty revenue (a) +$487K (+58%); Co-development and research fees +$204K (+54%).